Novo Nordisk's Double Play: Digital Authority Meets Clinical Depth as Semaglutide's Reach Widens

Wegovy tops AI searches; semaglutide shows 63% MASH resolution; oral pill gains momentum. Novo Nordisk faces mixed Q1 sales due to 340B.

Novo Nordisk is drawing strength from two distinct pillars this month. One is the invisible influence of artificial intelligence in shaping consumer choices; the other is a clinical push into a liver disease that affects a quarter of a billion people globally. Together, they underscore just how much the company's GLP-1 franchise, anchored by semaglutide, has expanded beyond the familiar territory of weight loss and diabetes.

The digital piece comes from a study by the 5W AI Visibility Index, which analysed more than 60 common consumer queries across ChatGPT, Claude, Perplexity and Google AI Overviews. Wegovy topped the rankings with a citation share of 19.0%, followed by Eli Lilly's Zepbound at 16.0%. Novo Nordisk's Ozempic claimed third place with 13.0%, while Saxenda landed at 2.0%. Together, the top five GLP-1 drugs — including Mounjaro — captured roughly 57% of all mentions in the weight management and metabolic health category. The metric measures discoverability and digital authority, not clinical efficacy or safety, but for Novo Nordisk it confirms that its brands dominate the chatbot-driven search landscape at a time when patients increasingly turn to AI for health information.

On the clinical side, the company is preparing to unveil new analyses from its ESSENCE programme at the EASL congress in Barcelona, running from May 27 to 30. The focus is MASH — metabolic dysfunction-associated steatohepatitis, a progressive fatty liver condition that coincides with obesity and type 2 diabetes. Semaglutide 2.4 mg (marketed as Wegovy) already holds an accelerated FDA approval for MASH in adults with moderate-to-severe fibrosis, and the ESSENCE data will include liver safety profiles, subgroup analyses for Japanese patients and postmenopausal women, as well as real-world evidence on disease burden and treatment costs. A previous interim analysis showed that 63% of Wegovy patients achieved MASH resolution without worsening fibrosis, versus 34% on placebo, while fibrosis improved in 37% of patients on the drug compared with 22% in the placebo arm.

The financial backdrop to both developments remains mixed. In the first quarter of 2026, reported sales fell 4% on an adjusted constant-currency basis, pinched by a one-off impact from the US 340B drug pricing programme. But the obesity division stood out, with adjusted revenues climbing 22% on the same basis. The oral Wegovy pill, launched in the US on January 5, has already built momentum: it surpassed 200,000 weekly prescriptions by late April and accumulated roughly 1.3 million scripts in the first quarter, translating into revenue of approximately 2.3 billion Danish kroner — though this was flattered by upfront stocking by wholesalers and telemedicine partners.

The stock reflects the tension between these divergent signals. It fell 1.4% on Thursday to €38.31, but has since recovered to around €38.86, leaving it up about 16% over the past month yet still 13% lower year-to-date. The company raised its guidance earlier this month on the back of stronger GLP-1 volumes, but still expects full-year adjusted sales and operating profit to decline by between 4% and 12%.

For investors, the next key test comes in Barcelona, where the ESSENCE data will offer a read on whether semaglutide's platform credentials extend convincingly into liver disease. The AI-visibility index, meanwhile, serves as a reminder that Novo Nordisk's marketing firepower remains unmatched in the consumer digital sphere. Neither dataset resolves the hard questions about pricing pressure, capacity constraints, or the head-to-head race with Eli Lilly — the half-year results on August 5 and a capital markets day on September 21 will do that. But together they reinforce a central thesis: semaglutide is no longer just a weight-loss drug, and Novo Nordisk is fighting on more than one front to keep it there.